• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

哮喘或慢性阻塞性肺疾病退伍军人的β受体阻滞剂治疗

beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease.

作者信息

Barnett Mitchell J, Milavetz Gary, Kaboli Peter J

机构信息

Center for Research in the Implementation of Innovative Strategies in Practice, Iowa City Veterans Administration Medical Center, University of Iowa, Iowa City, Iowa 52246, USA.

出版信息

Pharmacotherapy. 2005 Nov;25(11):1550-9. doi: 10.1592/phco.2005.25.11.1550.

DOI:10.1592/phco.2005.25.11.1550
PMID:16232018
Abstract

STUDY OBJECTIVES

To determine whether an association exists between health care resource use and beta-blocker therapy in patients with asthma or chronic obstructive pulmonary disease (COPD), and to determine whether any significant differences exist between type of beta-blocker agent administered and resource use.

DESIGN

Retrospective cohort study.

DATA SOURCE

Three Veterans Administration (VA) databases with information from hospitals and clinics in Iowa and Nebraska. Patients. A total of 8390 veterans with a diagnosis of asthma or COPD receiving treatment with a beta-blocker or another cardiovascular agent.

MEASUREMENTS AND MAIN RESULTS

Clinic visits and hospital admissions for asthma or COPD that occurred in 2000-2001 were identified using electronic administrative data files. Analyses were adjusted for comorbidity and patient demographics. Mean patient age was 67 years, and 97% of the patients were men. In unadjusted analyses, patients taking beta-blockers had more hospital admissions, similar inpatient length of stay (LOS), and fewer outpatient clinic visits for asthma or COPD. In adjusted analyses, however, no difference was noted in the odds of hospital admission or in LOS, and patients had fewer clinic visits related to asthma or COPD. The hazard ratio for hospital admission for asthma or COPD during the observation year was similar for patients taking and not taking beta-blockers, and no difference was noted with selective versus nonselective beta-blockers. However, the hospital admission rate was lower with atenolol than metoprolol.

CONCLUSION

Patients taking beta-blockers did not have more hospital admissions or clinic visits for their asthma or COPD than patients not taking these agents. When clinically indicated, beta-blockers-especially atenolol-should be considered for patients with asthma or COPD.

摘要

研究目的

确定哮喘或慢性阻塞性肺疾病(COPD)患者的医疗资源使用与β受体阻滞剂治疗之间是否存在关联,并确定所使用的β受体阻滞剂类型与资源使用之间是否存在显著差异。

设计

回顾性队列研究。

数据来源

来自爱荷华州和内布拉斯加州医院及诊所信息的三个退伍军人管理局(VA)数据库。患者。共有8390名诊断为哮喘或COPD并接受β受体阻滞剂或其他心血管药物治疗的退伍军人。

测量指标及主要结果

使用电子管理数据文件确定2000 - 2001年发生的哮喘或COPD门诊就诊和住院情况。分析针对合并症和患者人口统计学进行了调整。患者平均年龄为67岁,97%为男性。在未调整的分析中,服用β受体阻滞剂的患者因哮喘或COPD的住院次数更多,住院时间相似,门诊就诊次数更少。然而,在调整分析中,住院几率或住院时间并无差异,且患者与哮喘或COPD相关的门诊就诊次数更少。在观察年度,服用和未服用β受体阻滞剂的患者因哮喘或COPD住院的风险比相似,选择性与非选择性β受体阻滞剂之间未发现差异。然而,阿替洛尔的住院率低于美托洛尔。

结论

服用β受体阻滞剂的哮喘或COPD患者的住院次数和门诊就诊次数并不比未服用这些药物的患者多。在有临床指征时,哮喘或COPD患者应考虑使用β受体阻滞剂,尤其是阿替洛尔。

相似文献

1
beta-Blocker therapy in veterans with asthma or chronic obstructive pulmonary disease.哮喘或慢性阻塞性肺疾病退伍军人的β受体阻滞剂治疗
Pharmacotherapy. 2005 Nov;25(11):1550-9. doi: 10.1592/phco.2005.25.11.1550.
2
Rates of hospitalizations and emergency department visits in patients with asthma and chronic obstructive pulmonary disease taking beta-blockers.使用β受体阻滞剂的哮喘和慢性阻塞性肺疾病患者的住院率和急诊就诊率。
Pharmacotherapy. 2007 May;27(5):684-90. doi: 10.1592/phco.27.5.684.
3
Use of beta blockers and the risk of death in hospitalised patients with acute exacerbations of COPD.β受体阻滞剂的使用与慢性阻塞性肺疾病急性加重住院患者的死亡风险
Thorax. 2008 Apr;63(4):301-5. doi: 10.1136/thx.2007.081893. Epub 2007 Oct 19.
4
Comparison of levalbuterol and racemic albuterol in hospitalized patients with acute asthma or COPD: a 2-week, multicenter, randomized, open-label study.在住院急性哮喘或慢性阻塞性肺疾病患者中比较左旋沙丁胺醇和消旋沙丁胺醇:一项为期2周的多中心随机开放标签研究。
Clin Ther. 2008;30 Spec No:989-1002. doi: 10.1016/j.clinthera.2008.06.010.
5
Beta-blockers as single-agent therapy for hypertension and the risk of mortality among patients with chronic obstructive pulmonary disease.β受体阻滞剂作为高血压单药治疗及慢性阻塞性肺疾病患者的死亡风险
Am J Med. 2004 Dec 15;117(12):925-31. doi: 10.1016/j.amjmed.2004.07.043.
6
Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease.β受体阻滞剂可能降低慢性阻塞性肺疾病患者的死亡率和急性加重风险。
Arch Intern Med. 2010 May 24;170(10):880-7. doi: 10.1001/archinternmed.2010.112.
7
Mortality risk in patients receiving drug regimens with theophylline for chronic obstructive pulmonary disease.接受含茶碱药物治疗方案的慢性阻塞性肺疾病患者的死亡风险。
Pharmacotherapy. 2009 Sep;29(9):1039-53. doi: 10.1592/phco.29.9.1039.
8
Risk of hospitalizations/emergency department visits and treatment costs associated with initial maintenance therapy using fluticasone propionate 500 microg/salmeterol 50 microg compared with ipratropium for chronic obstructive pulmonary disease in older adults.与异丙托溴铵相比,使用丙酸氟替卡松500微克/沙美特罗50微克进行初始维持治疗的老年人慢性阻塞性肺疾病住院/急诊就诊风险及治疗费用。
Am J Geriatr Pharmacother. 2008 Aug;6(3):138-46. doi: 10.1016/j.amjopharm.2008.08.005.
9
Characteristics of spacer device use by patients with asthma and COPD.哮喘和慢性阻塞性肺疾病患者使用储雾罐装置的特征。
J Emerg Med. 2008 Nov;35(4):357-61. doi: 10.1016/j.jemermed.2008.01.012. Epub 2008 Aug 30.
10
[Heart failure: critical patients].[心力衰竭:重症患者]
G Ital Cardiol (Rome). 2007 Sep;8(9):568-73.

引用本文的文献

1
The safety of cardioselective β-blockers in asthma: literature review and search of global pharmacovigilance safety reports.心脏选择性β受体阻滞剂在哮喘中的安全性:文献综述及全球药物警戒安全性报告检索
ERJ Open Res. 2021 Mar 1;7(1). doi: 10.1183/23120541.00801-2020. eCollection 2021 Jan.
2
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.β肾上腺素能阻滞剂会增加哮喘恶化吗?一项随机对照试验的网络荟萃分析。
Sci Rep. 2021 Jan 11;11(1):452. doi: 10.1038/s41598-020-79837-3.
3
[Medical therapy of heart and lung diseases. Effects on the respective other organ].
心肺疾病的医学治疗。对各自其他器官的影响。
Herz. 2014 Feb;39(1):15-24. doi: 10.1007/s00059-013-4035-4.
4
Use of beta-adrenoceptor antagonists in older patients with chronic obstructive pulmonary disease and cardiovascular co-morbidity: safety issues.β-肾上腺素能受体拮抗剂在患有慢性阻塞性肺疾病且合并心血管疾病的老年患者中的应用:安全性问题。
Drugs Aging. 2008;25(2):131-44. doi: 10.2165/00002512-200825020-00005.
5
Tips and tricks on outpatient initiation and uptitration of beta-blockade in heart failure.心力衰竭患者门诊启动和滴定β受体阻滞剂的技巧与窍门
Curr Heart Fail Rep. 2007 Jun;4(2):110-6. doi: 10.1007/s11897-007-0009-2.
6
Hemokinins and endokinins.血激肽与内激肽。
Cell Mol Life Sci. 2004 Jul;61(13):1652-63. doi: 10.1007/s00018-004-4035-x.